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Vascular-targeted therapies have shown promise as adjuvant cancer treatment. As these agents undergo clinical eval-
uation, sensitive imaging biomarkers are needed to assess drug target interaction and treatment response. In this
study, dynamic contrast enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DW-MRI) were evaluated for detecting
response of intracerebral 9 L gliosarcomas to the antivascular agent VEGF-Trap, a fusion protein designed to bind all
forms of Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PGF). Rats with 9 L tumors were
treated twice weekly for two weeks with vehicle or VEGF-Trap. DCE- and DW-MRI were performed one day prior to
treatment initiation and one day following each administered dose. Kinetic parameters (Ktrans, volume transfer con-
stant; kep, efﬂux rate constant from extravascular/extracellular space to plasma; and vp, blood plasma volume fraction)
and the apparent diffusion coefﬁcient (ADC) over the tumor volumes were compared between groups. A signiﬁcant
decrease in kinetic parameters was observed 24 hours following the ﬁrst dose of VEGF-Trap in treated versus control
animals (p<0.05) and was accompanied by a decline in ADC values. In addition to the signiﬁcant hemodynamic effect,
VEGF-Trap treated animals exhibited signiﬁcantly longer tumor doubling times (p< 0.05) compared to the controls.
Histological ﬁndings were found to support imaging response metrics. In conclusion, kinetic MRI parameters and
change in ADC have been found to serve as sensitive and early biomarkers of VEGF-Trap anti-vascular targeted therapy.
Copyright © 2011 John Wiley & Sons, Ltd.
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INTRODUCTION
In Phase III clinical testing, Stupp and colleagues demonstrated the
efﬁcacy of concurrent temozolomide and radiation for treating
newly diagnosed glioblastoma (1). With an improvement ofmedian
survival from 12months to 14months, this treatment regimen has
become the standard of care. Although radiotherapy plus concom-
itant temozolomide provides a clinically meaningful and signiﬁcant
survival beneﬁt, the prognosis remains poor for most patients with
malignant gliomas. A number of molecularly targeted therapies are
being investigated for their potential to signiﬁcantly improve the
outcome for these patients (2,3).
Anti-angiogenic and antivascular therapies are at the forefront
of development as viable treatment options for solid tumors
(4,5). Recent clinical trials have shown that such agents, e.g.
Bevacizumab, provide improved efﬁcacy for the treatment of re-
current brain tumors (6). The requirement of malignant gliomas
for a continual supply of nutrients and oxygen provided by a vast
network of newly forming intratumoral vessels, provides a sound
scientiﬁc rationale for targeting tumor angiogenesis. Vascular
Endothelial Growth Factor (VEGF) is one of the principal driving
forces for tumors to maintain their highly proliferative potential.
Elevated stimulation of angiogenesis through the production of
VEGF occurs predominantly in high-grade tumors (7). Recent
studies have also shown a signiﬁcant reduction in both vascular
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permeability and neovascular formation in tumors treated with
VEGF inhibitors (8–14) and have shown tumor regression in some
cases (15). VEGF-Trap (Regeneron Pharmaceuticals, Inc., Tarrytown,
NY), currently in clinical trials, is a decoy receptor protein effective
in inhibiting VEGF signaling by binding with a high afﬁnity to all
isoforms of VEGF-A and placental growth factor (9–11,15–20).
Preclinical studies have shown that this agent, when combined
with standard treatments encompassing chemotherapy as well
as radiotherapy, results in improved efﬁcacy (21–23). Ultimately,
these treatments are aimed at indirectly inhibiting tumor growth
and possibly inducing cell death by limiting the availability of vital
nutrients, which may improve the effectiveness of conventional
therapies (21,22).
Efforts are being made to evaluate imaging modalities to pro-
vide biomarkers of therapeutic-induced alterations in the tumor
vasculature. Monitoring of volumetric changes prior to and fol-
lowing treatment initiation is the current standard of practice
for assessing treatment effects. Although effective in predicting
clinical outcome to therapy, prognosis may take 2–3months fol-
lowing the start of treatment. Functional imaging complements
traditional anatomical imaging for improved diagnosis and
response assessment. Hemodynamic imaging techniques includ-
ing dynamic contrast enhanced (DCE) and dynamic susceptibility
contrast (DSC) MRI provide insights into tumor blood ﬂow, blood
volume and vessel permeability, which have shown promise as
sensitive biomarkers of treatment-induced response (23). Most
notably, DCE-MRI uses low contrast agent concentrations to pro-
duce signal enhancement, which can be tracked and ﬁt to a
pharmacokinetic model to extract such values as volume transfer
constant (Ktrans), the ﬂux rate constant between the extravascular
extracellular space and plasma (kep), and blood plasma volume
fraction (vp) (24–26). DCE-MRI has been used successfully to
show decreased Ktrans in tumors very early after anti-VEGF treat-
ments (8,12,13). A decrease in Ktrans has been correlated with
decreased growth rates and decreased levels of free VEGF, indi-
cating effective drug targeting. The apparent diffusion coefﬁ-
cient (ADC), a quantitative measure of water mobility calculated
from diffusion weighted (DW) MRI, has shown promise as a sen-
sitive and reliable biomarker for cytotoxic therapies (27–30) that
elicits a treatment-induced reduction in tumor cellularity (31).
Increased cell death has been correlated with an increase in
ADC. In this study, DCE- and DW-MRI were used to evaluate
cellular and hemodynamic response of 9 L rat brain tumors to a
VEGF-Trap antibody regimen.
EXPERIMENTAL
Animal tumor models
9 L glioma cells were obtained from the Brain Tumor Research
Center at the University of California at San Francisco. The cells were
grown as monolayers in 10 cm2 sterile plastic ﬂasks in Dulbecco’s
Modiﬁed Eagle Medium with 10% fetal bovine serum, 100 IU/mL
penicillin and 100mg/mL streptomycin, and 2mML-glutamine in
a 37 C incubator. Prior to implantation, cells were harvested by
trypsinization, counted, and re-suspended in serum-free medium
for injection.
Tumor implantation was performed in 17 male Fischer-344
rats, 7 to 9weeks old (Harlan Sprague–Dawley, Indianapolis, IN)
weighing between 125 and 150 g. Brieﬂy, animals were anesthe-
tized with a ketamine/xylazine mixture (87/13mg/kg) adminis-
tered intraperitoneally. A small incision was made over the right
hemisphere of the cranium. A 1-mm diameter burr hole was
drilled through the skull using a high-speed surgical drill, and a
5-mL suspension containing 2 105 9 L cells was slowly injected
at a depth of 3mm. The burr hole was ﬁlled with bone wax,
and the surgical area was cleaned using 70% ethanol. VetbondW
(3M, St. Paul, MN) was used to close the incision until healed.
Anti-angiogenic therapy
Once tumor volumes reached 20–60mm3 as determined using
MRI, pre-treatment DCE and DW-MR images were acquired for all
animals. Animals were then separated into two groups and were
treated with either 25mg/kg VEGF-Trap (n=10) or 12.5mg/kg
human Fc (vehicle protein) (n=7). Treatments were administered
subcutaneously twice weekly for two weeks (Fig. 1A).
MRI scans
MRI scans were performed on a 9.4 T, 16 cm horizontal bore
Varian (Palo Alto, CA) DirectDrive system with a quadrature rat
head coil (Doty Scientiﬁc, Inc., Columbia, SC). During all MRI pro-
cedures, animals were anesthetized with a 1–2% isoﬂuorane/air
mixture and body temperature was maintained using a heated
air system (Air-Therm, World Precision Instruments, Sarasota,
FL). MR images were acquired 24 h prior to treatment initiation
and 24 h after each treatment (Fig. 1A). Each MR experiment
consisted of a fast spin-echo-based T1-mapping sequence and
DCE- and DW-MRI sequences with a total overall acquisition time
for each imaging session of approximately 45min.
Figure 1. Diagrammatic presentation of study time points (A). Treat-
ments are highlighted in green, MRI (both DCE and DWI) are highlighted
blue, MRI and blood serum collection were performed on Day 11 (red),
and histological samples were taken at approximately Day 12 (yellow).
Plot showing relative change in tumor volume in control (diamond, solid
line) and treated (square, dotted line) groups over the study time period
(B). Treated animals generally showed a signiﬁcant slowing of tumor
growth compared to controls. Doubling times in the control and treated
groups were 3.76 ( 0.325) and 5.32 ( 0.319) days, respectively
(p=0.004). Signiﬁcance in relative change in volume between groups
occurred at days 8 and 11 post-therapy. Data are presented asmeans SEM.
Signiﬁcance was assessed at p< 0.05 and indicated by *.
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DW-MRI was performed using a spin-echo sequence with a
navigator echo for motion correction and gradient waveforms
sensitive to isotropic diffusion (32). Images were acquired using
the following parameters: repetition time/echo time (TR/TE) =
4000/47ms, ﬁeld of view (FOV) = 30mm, matrix size = 128 64,
slice thickness = 1mm, slice number = 13, and b-values (diffusion
weighting) of 120 and 1200 s/mm2.
DCE-MRI was performed using a T1-weighted gradient-echo
sequence with the following parameters: TR/TE = 85/3.2ms, ﬂip
angle = 20 , FOV= 30mm, matrix size = 128 64, slice thick-
ness = 1mm, slice number = 13 and averages = 2. Image datasets
were acquired over a 15-min period with a time resolution of
10.9 s. Following 1min of scanning (~6 images), a bolus dose of
gadolinium-DTPA (Magnevist, Bayer Healthcare Pharmaceuticals;
0.15mmol/kg, diluted 1:8.3 from 0.5mmol/mL in 0.9% saline
solution to 0.06mmol/ml) was administered via tail-vein catheter
at a rate of 4mL/min.
Image reconstruction and analysis
Tumors were manually contoured on the low-b images from the
DW-MRI sequence (b= 120 s/mm2). These volumes of interest
(VOI) were used to determine tumor volume and whole-tumor
mean values generated from quantiﬁcation of DW-MRI and
DCE-MRI data. Tumor doubling times were calculated for each
animal from exponential ﬁts in Excel (Microsoft, Redmond, WA)
to each individual growth time course (33).
Apparent diffusion coefﬁcients were calculated from the two
diffusion weightings (b-values) using the following equation:
ADC12 ¼ ln S1S2
 
= b2  b1ð Þ
where S1 and S2 are the signal intensities at b-values b1 = 120 s/mm
2
and b2 = 1200 s/mm
2, respectively, and ADC1-2 is the apparent
diffusion coefﬁcient obtained using b1 and b2.
Tumor kinetic parameters were determined by a voxel-wise
three-parameter ﬁt on the acquired time-resolved T1-weighted
images using a tri-exponential arterial input function (AIF) for
blood plasma concentration (Cp) (12):
Cp tð Þ ¼ A1 exp a1tð Þ þ A2 exp a2tð Þ þ A3 exp a3tð Þ
with A1 = 0.8259, A2 = 0.2230, A3 = 0.1565mM, a1 = 1.220,
a2 = 0.156, and a3 = 0.017/min. In this study, we followed the
referenced contrast injection procedure used for this AIF and
assumed negligible differences in AIF over time as well as between
animals. This AIF was incorporated into a generalized kinetic
model, equivalent to the efﬂux-corrected Patlak model (34,35):
Ct tð Þ ¼ Ktrans
Zt
0
Cp tð Þ exp kep t tð Þ
 
dtþ vpCp tð Þ
where Ktrans is the volume transfer constant, kep is the ﬂux rate con-
stant between extravascular extracellular space (EES) and plasma,
and vp is the blood plasma volume fraction. Fits were performed
using a non-linear least-squares algorithm, and goodness-of-ﬁt
(GoF) was monitored to conﬁrm reliable results; GoF was deﬁned
as the normalized root mean square error. Baseline signal intensity
was calculated as a mean from the ﬁrst ~6 images before contrast
injection excluding the ﬁrst image due to non-steady-state signal.
Tissue concentrations of contrast agent were determined using
the following equation: 1/T1 = R*[Gd-DTPA]+1/T10. The relaxivity
(R) was determined to be 5.5ml/(mmol s) by acquiring T1 maps of
1 cm3 syringes ﬁlled with saline (0.5M) and 13 Gd-DTPA concentra-
tions ranging from 0 to 10mM. The relaxation constant was
assumed constant between animals and time points. T10 is the T1
of the tumor tissue prior to injection of contrast agent. T10 was
set to 2.5 s which was the average of T1 measurements obtained
in each animal pre-therapy using a fast spin-echo sequence with
the following parameters: ﬁve TR values of 5, 1.5, 1, 0.8 and 0.6 s,
with 1, 1, 1, 2, and 4 averages, respectively; effective echo time
(TE)= 39.68ms, echo train length (ETL) = 4, 2 dummy scans, matrix
size= 128 256, FOV=3 cm, slice thickness= 1mm. Parameter
maps of Ktrans, kep, vp, and GoF were saved for the tumor VOI.
Non-enhancing tumor tissue within the VOI was excluded from
the analysis due to the model’s inability to accurately describe
the tissue’s kinetic properties. Therefore, voxels with lower than
0.35 GoF or 0.002 vp were excluded in mean tumor measurements.
All reconstruction and analyses were performed using in-house
programs written in MATLAB (The Mathworks, Natick, MA, USA).
Parameter maps shown in Figure 2 were interpolated to
256 256 matrix size for display only.
Histology
Three representative animals were randomly selected from each
group for tumor histology at approximately 12days post-treatment
initiation (Fig. 1A). 9 L tumors from control and treated animals
were placed in buffered formalin overnight, dehydrated in 70%
ethanol, and subsequently embedded in parafﬁn. Tissue sections
were prepared for histological processing by routine techniques.
Brieﬂy, parafﬁn sections (5mm thick) were cut on a microtome
and heated for 20min at 65 C. Slides were de-parafﬁnized in
xylene with three changes for 5min each, then rehydrated through
an alcohol gradient for 2min each (100% alcohol, 95% alcohol, 70%
alcohol). Some sections were ﬁrst stained using a Gill’s 2X hematox-
ylin solution followed by eosin, while others were stained using the
rabbit polyclonal antibody to Von Willebrand Factor III (vWf) to
highlight tissue vasculature, and counterstained for the nuclei. For
counting tumor vasculature, representative ﬁelds were obtained
from the vWf-stained slides at random on each of three controls
and three treated tumor slices. Brown-stained areas greater than
about 10mm in diameter were considered positive stains for the
purpose of counting. Positive stains were counted using IMAGEJ
software (NIH) and used to quantify the difference between groups.
On additional sections, ApopTag or Ki-67 stains were performed
using standard techniques to highlight apoptotic or proliferating
cells in the tumor, respectively.
Assessment of free and bound VEGF
Blood serum samples were collected through a tail-vein catheter
24h after the ﬁnal dose of VEGF-Trap (n=7) or vehicle (n=3)
(Fig. 1A). Samples were stored short-term in a 3 C refrigerator until
being shipped on ice to Regeneron Pharmaceuticals for analysis.
Free VEGF trap was measured using a sandwich ELISA method
in which hVEGF165 (Regeneron Pharmaceuticals, Inc) diluted in
0.05 M carbonate-bicarbonate buffer was used as the capture
protein at a concentration of 2 mg/mL. The antigen was VEGF-
Trap (Regeneron Pharmaceuticals, Inc.) prepared in 1% BSA (KP
Labs). Samples and standard were incubated for 2 h at room
temperature and the excess was removed in subsequent washes.
The bound material was then reported with a mouse monoclo-
nal antibody (P10 G1F6, Regeneron Pharmaceuticals, Inc) then
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a secondary antibody was used. Anti-mouse HRP (Jackson Labo-
ratories) TMB substrate (Sigma, T8665) was used in the color
development, the plates were read at 450–570 nm and results
analyzed using the SoftMax Pro 5.3 (Molecular Devices).
Bound endogenous rat VEGF was determined by an ELISA
developed using the antibody to Rat VEGF164 afﬁnity puriﬁed
polyclonal antibody (R&D Systems, Cat#AF564) as the capture
antibody. The antigen was prepared fresh with rVEGF bound to
two molar quantities of the VEGF-Trap and allowed to incubate
at room temperature for 1 h. This complex was used to generate
a standard curve. Samples were bound to the plate, and after
washing away the unbound rVEGF the unknown and controls
were reported with an anti-human Fc IgG (Sigma, A-0170).
The captured protein used in this assay was recombinant rat
VEGF at 2mg/mL in 0.05 M carbonate-bicarbonate buffer. The
antigen usedwas themousemonoclonal antibody P10 (Regeneron
Pharmaceuticals, Inc), which was reported using a goat anti-mouse
antibody (Jackson Laboratories) and the samples were reported
with an anti-rat antibody (Promega). The samples were diluted
1:1000 to dilute out the serum effects of this assay.
Statistics
A paired Student’s t-test was used to compare the percent
change of parameter values between pre- and post-therapy time
points for each animal. An unpaired Student’s t-test was used to
perform group comparisons in percent change of parameter
values at each time point and tumor doubling times. Results
were declared statistically signiﬁcant at the two-sided 5% com-
parison-wise signiﬁcance level (p< 0.05). Values are given as
means SEM.
RESULTS
Therapeutic intervention was initiated at tumor volumes of
35.8 5.0mm3 and 36.4 8.6mm3 for VEGF-Trap therapy and
vehicle-treated control animals, respectively. Based on ELISA anal-
yses, VEGF-Trap proved effective at binding to virtually all endog-
enous VEGF with no detectable VEGF and excess VEGF-Trap within
the blood samples tested (Table 1). Data for the control group
were not presented due to the absence of VEGF-Trap and VEGF
Figure 2. T2-weighted images with color overlays of parametric maps are shown for a representative animal in the control group (A–D) and the VEGF-
Trap-treated group (E–H) prior-to (Day 1, left image) and following (Day 1, right image) the initial treatment. The initial drop for the VEGF-Trap-treated
group in Ktrans (27%), kep (12%), and vp (64%) can clearly be seen here (E–G). ADC shows a small, but signiﬁcant drop (7%) by the ﬁrst day post-therapy
(H). Tumor heterogeneity was observed at individual time points. Nevertheless response to VEGF-Trap did not vary spatially throughout the tumor.
Table 1. ELISA analysis of endogenous VEGF
Free VEGF-Trap Bound VEGF Free Rat VEGF
VEGF-Trap 98 660 11 529 1540.45 149.30 0.00 0.00
BLQ 359 309 783
ELISA analysis was performed to assess the effectiveness of VEGF-Trap in attenuating the signaling of free rat VEGF. Blood serum
levels were measured on Day 11 post-treatment. Free VEGF-Trap, unbound VEGF-Trap; Bound VEGF, VEGF/VEGF-Trap complex;
Free Rat VEGF, unbound endogenous VEGF; BLQ, Below Level of Quantiﬁcation. Quantities are shown as group mean SE
(n=7). All units are ng/mL. VEGF levels for control animals were immeasurable and are not shown.
B. A. HOFF ET AL.
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levels being below quantiﬁcation. Low levels of endogenous VEGF
in non-VEGF-Trap treated animals have been reported in previous
studies (19,36). As shown in Figure 1B, inhibition of VEGF signaling
within the tumor resulted in signiﬁcantly larger percentage
changes in control tumor volumes at 8 and 11days post-treatment
initiation than those observed for VEGF-Trap treated tumors
(p< 0.05). Tumor volume doubling times were also affected as
evidenced by values of 3.76 ( 0.325) and 5.32 ( 0.319) days for
vehicle and VEGF-Trap groups, respectively (p=0.004).
Representative vascular kinetic and diffusion parameter maps
are shown as color overlays in Figure 2. Partial-voluming effects
are apparent in Figure 2, evidenced by reduced kinetic measure-
ments on the periphery of the color overlays. In vehicle-treated
animals, negligible changes in parameter values were observed
one day post-treatment initiation compared to the pre-treatment
baseline (Fig. 2A–D). In striking contrast, a single treatment with
VEGF-Trap resulted in a substantial decrease in all kinetic para-
meters (Fig. 2E–H) consistent with successful drug targeting. In
general, all kinetic parameters showed spatial variability within
the 9 L tumors at any given time point. Nevertheless, a spatially
uniform response to VEGF-Trap was observed throughout the
tumor for all kinetic metrics.
The two kinetic transfer constants, Ktrans and kep, and blood vol-
ume fraction (vp) were found to be dependent on VEGF-Trap treat-
ment, again consistent with strong effectiveness in target modula-
tion by the drug (Fig. 3). The reduction in Ktrans was observed
following the ﬁrst day of treatment, with a signiﬁcant difference
in Ktrans (27 3.1%, p=0.002) when compared to vehicle-treated
animals. Similar trends were observed for vp with a change of
63 2.3% (p< 0.001). Subsequent to the initial decrease, parame-
ter values plateaued and remained stable throughout the rest of
the treatment cycle. A gradual reduction in kep resulted in signiﬁ-
cant differences between the two treatment groups by Day 3
post-treatment initiation (Fig. 3). The maximum change in
kep (34.6 5.8%, p=0.007) was observed at Day 11.
In line with the kinetic parameters, ADC values declined
following VEGF-Trap treatment (Fig. 3). Although not as pro-
nounced as the changes in kinetic metrics, a signiﬁcant reduc-
tion in the change in ADC values was observed in VEGF-Trap
treated tumors when compared to controls for all time points af-
ter treatment. ADC values did not reach a minimum value until
Day 8 with a percentage decrease of 17.8 3.2% (p= 0.027).
Although ADC values for VEGF-Trap animals increased slightly
from Day 8 to 11, this change was not signiﬁcant.
Histological sections of representative animals from control
(n=3) and treated (n=3) groups taken 24 hours after the last
treatment (11 days post-initial-treatment) were subjected to
H&E, Ki-67, Von Willebrand / Factor VIII (vWF) and ApopTag stain-
ing. As observed in Figure 4, a 14% reduction in Ki-67 staining
was observed for VEGF-Trap treated tumors. This difference,
although consistent with reduced proliferative potential, was
not signiﬁcant (p= 0.25). In contrast, vWF stained sections
revealed that vessel numbers were signiﬁcantly lower in VEGF-
Trap-treated versus vehicle-treated animals (p= 0.011; Fig. 5). In-
terestingly, ApopTag staining revealed that apoptosis appeared
to be localized within the endothelial cells of the vasculature,
as shown by heavily stained regions in Figure 6. In contrast,
tumor tissue did not show signiﬁcant staining, and was therefore
not quantiﬁed and compared between groups. The results
observed in Figure 6 are consistent with the loss in vessel
number (Fig. 5) as well the reduction in MRI-determined kinetic
measures (Fig. 3). However, loss of vasculature due to VEGF
Figure 3. Plots of relative change in kinetic and diffusion parameters for the treated group (diamond, dotted line) shown together with the control
(square, solid line). A signiﬁcant decrease in Ktrans and vp occurred on the ﬁrst day post-therapy and persisted throughout the study. Tumor ADC steadily
decreased in VEGF-Trap treated tumors up to 15% from the initial value. In contrast, kep continued to decrease throughout the study. Data are pre-
sented as means SEM. Signiﬁcance was assessed at p< 0.05 and indicated by * under their respective p-values. Baseline parameter values for vehicle
and VEGF-Trap treated animals are: for Ktrans, 2.4 0.1 104/s and 2.3 0.1 104/s (p=0.7), respectively; vp, 7.6 1.3 103 and 8.1 0.5 103
(p=0.7), respectively; kep, 1.9 0.1 103 and 1.9 0.1 103 (p=0.8), respectively; and ADC, 1.1 0.02 103mm2/s and 1.0 0.02 103mm2/s
(p=0.1), respectively.
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inhibition did not result in a reduction in tumor cellularity as
depicted by visual inspection of tumor nuclear staining as well
as lack of signiﬁcant ApopTag staining in the tumor (Fig. 6).
DISCUSSION
The development of molecular targeted cancer therapies repre-
sents an area of intense investigation. Consequently, a number
of clinical trials are underway encompassing a diverse array of
targets and agents. However, the primary endpoint used for
assessing therapeutic response continues to be gross tumor vol-
umetric change. This endpoint may not be the best choice for
measuring the effectiveness of those molecularly targeted
agents that do not uniformly elicit a signiﬁcant reduction in
tumor volume (37–39). Therefore, there is an impetus to explore
non-invasive quantitative imaging modalities, such as MRI and
positron emission tomography, for their potential to provide
non-invasive biomarkers of treatment response. In fact, DCE-
MRI and DW-MRI metrics have shown signiﬁcant promise as
biomarkers of early cancer therapeutic response (40,41). The goal
of this study was to evaluate DCE-MRI and DW-MRI for their
ability to detect and quantify the therapeutic response of glioma-
bearing animals treated with VEGF-Trap.
VEGF-Trap is extremely effective in binding VEGF and PGF
(15,18). The extent of VEGF-Trap binding to endogenous VEGF
was virtually complete following two weeks of treatment (Table 1).
This strong binding afﬁnity to endogenous VEGF was clearly
evident early in our MRI measurements. Vascular kinetic rates
and blood plasma volume fraction as measured by DCE-MRI were
highly sensitive to VEGF-Trap treatment. Subsequent to the ﬁrst
treatment, both Ktrans and vp diminished by approximately 30%
and 60%, respectively, suggesting an extremely rapid response
of tumor vasculature to VEGF-Trap. These vascular changes are
reﬂected in our vWF and ApopTag histological stains (Figs 5 and
6), which show a lower number of vWF-positive-stained blood
Figure 4. The proliferative potential of tumors following treatment with
vehicle (A) or VEGF-Trap (B) was determined by Ki-67 staining of samples
taken on Day 12. Positively identiﬁed nuclei were counted in randomly
selected ﬁelds. Representative micrographs for each group are shown.
The quantiﬁcation of the nuclei for each treatment group in 3–6
randomly selected ﬁelds per subject (C). Insigniﬁcant differences in Ki-67
positive nuclei were observed between treatment groups (p=0.25). Bar
plots are presented as the mean number of nuclei and SEM. Images were
acquired at 40 magniﬁcation.
Figure 5. Tumor vasculature following treatment with vehicle (A) or
VEGF-Trap (B) was determined by Von Willebrand factor staining of
samples taken on Day 12. Positively stained vessels were counted in
randomly selected ﬁelds. Representative micrographs for each group
are shown. The quantiﬁcation of the vessels for each treatment group
in 2–3 randomly selected ﬁelds per subject (C). A signiﬁcant decrease
in the number of vessels occurred in VEGF-Trap treated animals
(p=0.011). Bar plots are presented as the mean number of nuclei and
SEM. Images were acquired at 10 magniﬁcation.
Figure 6. Apoptosis and tumor cellularity following treatment with
vehicle (A) or VEGF-Trap (B) was determined by ApopTag staining of
samples taken on Day 12, superimposed on H&E. Extent of apoptosis
and tumor cellularity were assessed by visual inspection. Representative
micrographs for each group are shown. Treatment by VEGF-Trap resulted
in massive apoptotic events in the tumor vasculature but negligible
change in tumor cellularity when compared to vehicle-treated tumors.
Healthy and apoptotic vessels are indicated by yellow and red arrows,
respectively. A closer representative VEGF-Trap treated sample is shown
in C, highlighting the border between tumor epithelial and vessel endo-
thelial cells. Images were acquired at 20 (A&B) or 40 (C) magniﬁcation.
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vessels and greater ApopTag staining of vessel endothelial cells in
treated animals. These trends agree with those observed in both
preclinical and clinical investigations of tumor response to anti-
angiogenic and antivascular agents asmeasured by DCE-MRI (8,41).
An increase in tumor water mobility as determined by ADC
measurements has been associated with a reduction of tumor
cellularity as a consequence of massive cell kill (27). Treatment
by VEGF-Trap elicited no such response in ADC values, suggest-
ing no substantial decrease in tumor cellularity due to cell death.
Staining by H&E and ApopTag corroborated what was observed
by ADC. In fact, ADC values decreased signiﬁcantly following
VEGF-Trap treatment with a signiﬁcant drop observed as early
as one day post-treatment. Reiger and colleagues monitored
changes in DSC-MRI and DW-MRI quantitative metrics during
Bevacizumab treatment in glioma patients, observing a similar
trend in ADC (41). In their clinical study, a drop in tumor blood
volume as well as water mobility within the tumor was reported
by 8weeks post-treatment initiation. The reduction of ADC was
attributed to pathological changes in the tumor, which may
result in a decrease in extracellular water content and narrowing
of extracellular space due to treatment-induced hypoxia. This
would result in an increase in tumor cellularity per unit volume,
which is inversely related to ADC values.
Numerous models for assessing pharmacokinetic qualities
in vivo with varying assumptions have been proposed. In this
study we used an established model that assumes the fast-
exchange limit to analyze our DCE-MRI data. This technique has
been well-documented but recent studies have provided more
robust models including the shutter-speed approach developed
by Yankeelov and colleagues in 2003 (34). This model has shown
greater accuracy in quantifying permeability kinetics but has only
recently seen more extensive application. Although more accu-
rate, the sensitivity of the newer models to therapeutic response
have yet to be tested against established pharmacokinetic models.
Such an analysis is beyond the scope of this study.
The impairment of VEGF signaling activity in the 9 L glioma
model resulted in apoptosis of the vascular endothelial cell popu-
lation, which likely contributed to the overall reduction in tumor
vessel numbers. The observed decrease in tumor vessel density
is also in agreement with previously reported results of the use
of antivascular agents on gliomas (42–45). However, in these
previous studies, apoptosis of endothelial cells was not reported
following VEGF-Trap treatment. Erber and colleagues showed that
targeting VEGFR-2 and PDGFR-b signaling using the tyrosine
kinase inhibitor SU6668 in a C6 rat tumor model resulted in endo-
thelial cell apoptosis and reduced tumor growth rate (46). This is in
agreement with our results, which show a similar reduced growth
rate as reﬂected in our volume measurements as well as Ki-67
staining (Fig. 1B and 4) that show a slightly diminished fraction
of proliferating cells.
In conclusion, this study supports the utility of DCE- and DW-
MRI in monitoring the effectiveness of angiogenesis-targeted
cancer therapy, in this case response to VEGF-Trap. The ability
to track therapeutic effectiveness with non-invasive imaging
biomarkers is especially important for gliomas because biopsies
during the course of treatment are not an option (unlike most
other histotypes that are amenable to pharmacodynamic bio-
markers). The use of these MRI modalities is especially compel-
ling as angiogenesis targets are prominently being tested in
the glioma population. Besides Aﬂibercept (VEGF-Trap), there are
a number of other targeted agents in current clinical trials for
treating glioma patients, e.g. Zactima (vandetanib, ClinicalTrials.
gov ID: NCT00272350), cediranib (AZD2171) (35), ramucirumab
(ClinicalTrials.gov ID: NCT00895180), BIBF1120 (ClinicalTrials.gov
ID: NCT01380782), as well as numerous bevacizumab (Avastin;
ClinicalTrials.gov ID: NCT00782756) (47–49) combination trials.
Studies are underway to extend this proof-of-principle to the
study of the broader angiogenesis portfolio to build a compelling
case for clinical trial incorporation. Overall, MRI biomarkers have
signiﬁcant potential for not only monitoring treatment effects
but also for optimization of drug dose and schedules.
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